Prognostic Parameters for the Primary Care of Melanoma Patients: What Is Really Risky in Melanoma?

Table 1

Genetic mutations and corresponding current and future targeted therapies.

Pathway	Target	Therapy
MAP-kinase	Receptor tyrosine kinase	Imatinib
		Dasatinib
		Nilotinib
		Masitinib
	BRAF	GSK2118436
		Vemurafenib
	NRAS	Sorafenib
		Tipifamib
	CRAS	Lonafamib
		RAF265
PI3AK	mTor	Sirolimus
		Temsirolimus
		Everolimus
	PI3, AKT	GDC0941, GSK2126458, BEZ235, BKM120, XL765, MK2206, GSK 690693
MITF	CDK2, HDAC	SCH727965, panobinostat
WNT	B catenin	Small molecular antagonists
		RNA aptamers